Bavisant

DB12299InvestigationalSmall molecule

Bavisant has been used in trials studying the basic science and treatment of Alcoholism, Pharmacokinetics, Drug Interactions, Attention Deficit Hyperactivity Disorder, and Attention Deficit Disorders With Hyperactivity.

Mechanism: Pharmacologically active on Histamine H3 receptor
Curator reviewed
Formula / weight: C₁₉H₂₇N₃O₂ · 329.444 g/mol (avg)
Code names: JNJ-31001074

Resolves to

Compound

UNII9827P7LFVHCAS929622-08-2ChEMBLCHEMBL2103862PubChem16061509

Structure

InChIKeyBGBVSGSIXIIREO-UHFFFAOYSA-NSMILESO=C(N1CCN(CC1)C1CC1)C1=CC=C(CN2CCOCC2)C=C1

Targets

Q9Y5N1HRH3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bavisant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account